Yes, I think tomorrow will show a continued follow through and perhaps a continuing volume expansion.
Level II seems to suggest that.
I think a ceo/pharma tie in is going to break soon. I believe it's part of the board's immediate short term plan along with the upcoming human trials.
There are other pr's from blood platelets, etc., on that are additional bullish dimension of ACTC.
It think it's important to keep in mind, that as the eye regenerative technology advances world-wise, the old axiom of those there first, usually are best positioned to benefit the most. Top management to bring this about, in harmony with the accomplishments of Dr. Lanza and his team, will prove to be a winning combination going forward for ACTC.
News 
Market Data 
Discover 
